OptionsHouse

Options Trading News

August 3, 2012  Fri 2:32 AM CT

ZIOP: SEE CHART GET CHAIN FIND STRATEGIES
Someone is looking for volatility to pick up in ZioPharm Oncology.

optionMONSTER's tracking systems detected the purchase of 2,469 January 5 puts for $0.80 against open interest of just 63 contracts. Several large blocks of shares were purchased shortly after, apparently creating a so-called delta-neutral trade.

Owning puts and stock at the same time makes the investor directionally neutral on the drug developer. They stand to profit, however, from implied volatility increasing because that will inflate the value of the options. Using long-dated contracts increases the sensitivity to the change because they have a higher vega. (See our Education section)

He or she is probably looking forward to results from the ongoing Phase 3 trials of ZIOP's Palifosfamide cancer drug. Option premiums often increase as the market anticipates such data, which can make or break a company's future. Implied volatility currently stands at 57 percent versus its 38 percent historical propensity to move.

The shares rose 4.29 percent to $5.59 yesterday. It reported quarterly results after the bell, but earnings usually don't matter for a development-stage companies like ZIOP.

The delta-neutral trade pushed total option volume in the name to 9 times greater than average.
Share this article with your friends


Related Stories

ZIOP

Ziopharm put sale bets on end to slide

September 9, 2016

The cancer-treatment developer is down 26 percent in the last three months, but one trader apparently believes that further downside will be limited.

OptionsHouse

Premium Services

Education & Strategy

Using spreads to minimize risk

Last week we discussed the risk vs reward profile of a debit call spread in Wells Fargo (WFC). This week we will run thru the risk vs reward of selling a credit put spread to achieve the same exposure of that debit call spread.

View more education articles »